Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial

@article{Derman2006OralMI,
  title={Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial},
  author={Richard J. Derman and Bhalchandra S. Kodkany and Shivaprasad S. Goudar and Stacie E Geller and Vijaya A. Naik and Mb Bellad and Shobhana Suresh Patted and Ashlesha Patel and Stanley A. Edlavitch and Tyler D. Hartwell and Hrishikesh Chakraborty and Nancy E. Moss},
  journal={The Lancet},
  year={2006},
  volume={368},
  pages={1248-1253}
}
BACKGROUND Postpartum haemorrhage is a major cause of maternal mortality in the developing world. Although effective methods for prevention and treatment of such haemorrhage exist--such as the uterotonic drug oxytocin--most are not feasible in resource-poor settings where many births occur at home. We aimed to investigate whether oral misoprostol, a potential alternative to oxytocin, could prevent postpartum haemorrhage in a community home-birth setting. METHODS In a placebo-controlled trial… Expand
From research to action: Oral Misoprostol for preventing postpartum haemorrhage during home delivery in rural Bangladesh
TLDR
Oral misoprostol should be included in the National Maternal Health Strategy as an intervention to control PPH during home birth in rural Bangladesh during home births that take place without trained birth attendants. Expand
Prevention of postpartum haemorrhage: cost consequences analysis of misoprostol in low-resource settings
TLDR
Misoprostol could be an effective and cost-saving choice where oxytocin is not or cannot be used due to a lack of skilled birth attendants, inadequate transport and storage facilities or where a quality assured oxytoc in product is not available. Expand
The MamaMiso study of self-administered misoprostol to prevent bleeding after childbirth in rural Uganda: a community-based, placebo-controlled randomised trial
TLDR
This study has shown that antenatally distributed, self-administered misoprostol can be appropriately taken by study participants, and the rarity of the primary outcome means that a very large sample size would be required to demonstrate clinical effectiveness. Expand
Postpartum misoprostol for preventing maternal mortality and morbidity.
TLDR
To review maternal deaths and severe morbidity in all randomised trials of misoprostol for prevention or treatment of PPH, a large number of women will be needed to obtain robust estimates of maternal mortality, and cluster- and quasi-randomised trials are planned. Expand
Oral misoprostol for preventing postpartum haemorrhage in home births in rural Bangladesh: how effective is it?
TLDR
Community-based distribution of oral misoprostol by lay community health workers appeared to be effective, safe, acceptable, and feasible in reducing the incidence of PPH in rural areas of Bangladesh. Expand
Effectiveness of Misoprostol for the Prevention of Postpartum Haemorrhage: A Review
TLDR
Misoprostol was found to be as effective as oxytocin in the prevention of PPH in developing countries and sublingual route at the dose of 400 µg seems to be better in minimizing the adverse side-effects. Expand
Administration of misoprostol by trained traditional birth attendants to prevent postpartum haemorrhage in home births in Pakistan: randomised placebo‐controlled trial
  • C. Mammen, M. Sharma
  • Medicine
  • BJOG : an international journal of obstetrics and gynaecology
  • 2011
TLDR
It would have been more informative if the trial could have been conducted comparing the efficacy and adverse effect profile of a higher and lower dose of misoprostol, because several studies have shown a similar efficacy with the same dose regimen and placebo in a similar setting. Expand
Misoprostol for prevention and treatment of postpartum haemorrhage: A systematic review.
TLDR
The use of misoprostol was not associated with any significant reduction in the incidence of PPH, and specialised investigations of its dose and routes of administration for clinically significant effects and acceptable side effects are warranted. Expand
Misoprostol for the prevention and treatment of postpartum haemorrhage.
TLDR
There is very limited evidence for the effectiveness of misoprostol, the lowest effective dose and the magnitude of adverse effects, both direct and indirect; the need for further research is a matter of great urgency. Expand
Effectiveness and safety of misoprostol distributed to antenatal women to prevent postpartum haemorrhage after childbirths : a stepped-wedge cluster-randomized trial
Background: Oral misoprostol, administered by trained health-workers is effective and safe for preventing postpartum haemorrhage (PPH). There is interest in expanding administration of misoprostol byExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
WHO multicentre randomised trial of misoprostol in the management of the third stage of labour
TLDR
A multicentre, double-blind, randomised controlled trial to determine whether oral misoprostol is as effective as oxytocin during the third stage of labour and the use of additional uterotonics without an unacceptable level of side-effects. Expand
A multicentre randomized controlled trial of oral misoprostol and i.m. syntometrine in the management of the third stage of labour.
TLDR
Oral misoprostol might be used in the management of the third stage of labour, especially in situations where the use of syntometrine is contraindicated and facilities for storage and parenteral administration of oxytocics are limited. Expand
Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomised double blind clinical trial
TLDR
Sublingual misoprostol reduces the frequency of severe postpartum haemorrhage and decreases in haemoglobin concentration after delivery. Expand
A randomised controlled trial of misoprostol versus oxytocin in the active management of the third stage of labour
  • V. Oboro, T. O. Tabowei
  • Medicine
  • Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • 2003
TLDR
It is concluded that oral misoprostol can replace intramuscular oxytocin in reducing postpartum haemorrhage in low-risk women, in developing countries, especially as it is administered orally and it is thermostable in tropical conditions. Expand
Side-effects of oral misoprostol in the third stage of labour--a randomised placebo-controlled trial.
TLDR
This study has shown the association of postpartum oral misoprostol 600 micrograms with shivering, pyrexia and hypertension, and possible effects on blood loss may have been obscured by the lesser use of additional oxytocics in the misop frostol group. Expand
Initiating a novel therapy in preventing postpartum hemorrhage in rural India: a joint collaboration between the United States and India.
TLDR
A joint U.S. and Indian collaboration to test the efficacy and the feasibility of an innovative method to reduce PPH can serve as collaborative model to develop additional interventions to improve maternal mortality and morbidity. Expand
Misoprostol versus oxytocin in the third stage of labor
TLDR
Oral misoprostol is as effective as intramuscular oxytocin in the prevention of PPH and has potential in reducing the high incidence of P PH in developing countries. Expand
Misoprostol for prevention of postpartum hemorrhage
TLDR
Misoprostol administered as a micro‐enema, 400 μg in 5 ml of saline during the third stage of labor, appears to be as effective as oxytocin 10 IU, i.m., but misop Frostol produced more side effects than oxytoc in a double blind, randomized, clinical trial. Expand
Misoprostol in preventing postpartum hemorrhage: A meta‐analysis
  • C. Langenbach
  • Medicine
  • International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • 2006
TLDR
Conventional uterotonic drugs should not be used to set the lowest‐accepted level of effectiveness in settings where they are entirely unsuitable, and continuing to weigh the benefits of one effective drug against another only delays the distribution of misoprostol in countries where it is the only feasible choice and must be measured against no treatment at all. Expand
Prevention and treatment of postpartum hemorrhage: new advances for low-resource settings.
TLDR
New strategies to prevent and manage postpartum hemorrhage in developing countries, such as community-based use of misoprostol, oxytocin in the Uniject delivery system, the non-inflatable antishock garment to stabilize and resuscitate hypovolemic shock, and the balloon condom catheter to treat intractable uterine bleeding are reviewed. Expand
...
1
2
3
4
...